In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014∈-∈2015

BMC Microbiology

Volumn 15, Issue 1, 2015, Pages

  Deshmukh, Anand ^a   Hagen, Ferry ^b   Sharabasi, Ola Al ^a   Abraham, Mariamma ^a   Wilson, Godwin ^c   Doiphode, Sanjay ^a   Maslamani, Muna Al ^a   Meis, Jacques F ^b,d  

^a HAMAD GENERAL HOSPITAL   (Qatar)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c Al Khor Hospital   (Qatar)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antimicrobial susceptibility testing; Brucella melitensis; Brucellosis; Qatar

Indexed keywords

CIPROFLOXACIN; COTRIFAMOLE; DOXYCYCLINE; GENTAMICIN; STREPTOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; QATAR; REVIEW; RPOB GENE; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANIMALIA; BRUCELLA; BRUCELLA MELITENSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BRUCELLA MELITENSIS; BRUCELLOSIS; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; GENTAMICINS; HUMANS; IN VITRO TECHNIQUES; MICROBIAL SENSITIVITY TESTS; QATAR; RIFAMPIN; TETRACYCLINE;

EID: 84931264124     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-015-0458-9     Document Type: Review

References (30)

1. World Health Organization (WHO) 1997
2. Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: a re-emerging zoonosis. Vet Microbiol. 2010;140:392-8.
3. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006;6:91-9.
4. Corbel MJ. Brucellosis in humans and animals. Geneva (Switzerland): World Health Organization; 2006.
5. Robichaud S, Libman M, Behr M, Rubin E. Prevention of laboratory-acquired brucellosis. Clin Infect Dis. 2004;38:e119-22.
6. Lista F, Reubsaet FA, De Santis R, Parchen RR, de Jong AL, Kieboom J, et al. Reliable identification at the species level of Brucella isolates with MALDI-TOF-MS. BMC Microbiol. 2011;11:267.
7. Abdel-Maksoud M, House B, Wasfy M, Abdel-Rahman B, Pimentel G, Roushdy G, et al. In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance. Ann Clin Microbiol Antimicrob. 2012;11:24.
8. Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R. Genetic bases of the rifampicin resistance phenotype in Brucella spp. J Clin Microbiol. 2004;42:5439-43.
9. Valdezate S, Navarro A, Medina-Pascual MJ, Carrasco G, Saéz-Nieto JA. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis. J Antimicrob Chemother. 2010;65:51-3.
10. Gür D, Kocagöz S, Akova M, Unal S. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother. 1999;43:2337.
11. Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S, et al. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens. Int J Med Sci. 2011;8:198-202.
12. Marianelli C, Graziani C, Santangelo C, Xibilia MT, Imbriani A, Amato R, et al. Molecular epidemiological and antibiotic susceptibility characterization of Brucella isolates from humans in Sicily, Italy. J Clin Microbiol. 2007;45:2923-8.
13. Hashim R, Ahmad N, Mohamed Zahidi J, Tay BY, Mohd Noor A, Zainal S, et al. Identification and in vitro antimicrobial susceptibility of Brucella species isolated from human brucellosis. Int J Microbiol. 2014;2014:596245.
14. Kaya O, Akçam FZ, Yayll G. Investigation of the in vitro activities of various antibiotics against Brucella melitensis strains. Turk J Med Sci. 2012;42:145-8.
15. López-merino A, Contreras-rodríguez A, Migranas-ortiz R, Orrantia-gradín R, Hernández-oliva GM, Torres Y, et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis. 2004;36:636-8.
16. Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One. 2012;7:e32090.
17. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4:e317.
18. Pappas G, Siozopoulou V, Akritidis N, Falagas ME. Doxycycline-rifampicin: physicians' inferior choice in brucellosis or how convenience reigns over science. J Infect. 2007;54:459-62.
19. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336:701-4.
20. Colmenero JD, Fernandez-Gallardo LC, Agundez JA, Sedeno J, Benitez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994;38:2798-802.
21. Rahil AI, Othman M, Ibrahim W, Mohamed MY. Brucellosis in Qatar: a retrospective cohort study. Qatar Med J. 2014;1:25.
22. Goldstein BP. Resistance to rifampicin: a review. J Antibiot (Tokyo). 2014;67:625-30.
23. Sandalakis V, Psaroulaki A, De Bock PJ, Christidou A, Gevaert K, Tsiotis G, et al. Investigation of rifampicin resistance mechanisms in Brucella abortus using MS-driven comparative proteomics. J Proteome Res. 2012;11:2374-85.
24. Sayan M, Kilic S, Uyanik MH. Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey. J Infect Chemother. 2012;18:41-6.
25. Lubani MM, Dudin KI, Sharda DC, Ndhar DS, Araj GF, Hafez HA, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J. 1989;8:75-8.
26. Kinsara A, Al-Mowallad A, Osoba AO. Increasing resistance of Brucellae to co-trimoxazole. Antimicrob Agents Chemother. 1999;43:1531.
27. Easmon CS, Crane JP, Blowers A. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother. 1986;18(Suppl D):43-8.
28. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother. 1999;43:1298-300.
29. Pappas G, Christou L, Akritidis N, Tsianos EV. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect. 2006;12:823-5.
30. Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother. 2006;50:22-33.